Literature DB >> 15709172

Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma.

Youn-Soo Lee1, Alexander O Vortmeyer, Irina A Lubensky, Timothy W A Vogel, Barbara Ikejiri, Sophie Ferlicot, Gérard Benoît, Sophie Giraud, Edward H Oldfield, W Marston Linehan, Bin T Teh, Stéphane Richard, Zhengping Zhuang.   

Abstract

Von Hippel-Lindau (VHL) disease is characterized by multiple tumors in specific target organs. The tumors at different sites share distinct morphologic and genetic characteristics but their cell of origin is unknown. We show that VHL disease-associated renal clear cell carcinomas (RCC) consistently coexpress erythropoietin (Epo) and Epo receptor (EpoR). In addition, coexpression of Epo and EpoR is detected in many renal cysts, providing further evidence that renal cysts are potential precursors for RCC. In conjunction with VHL gene deficiency, coexpression of Epo and EpoR in renal cysts and tumors may reflect a developmental arrest in immature mesenchymal cells. Such arrest may lead to autocrine stimulation, cell proliferation, and renal tumor development, similar to tumorigenesis of VHL disease-associated hemangioblastomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709172

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  Targeted therapy for renal cell carcinoma: a new treatment paradigm.

Authors:  Thomas E Hutson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-07

Review 2.  Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.

Authors:  Chi-Chao Chan; Atif Ben Daniel Collins; Emily Y Chew
Journal:  Retina       Date:  2007-01       Impact factor: 4.256

3.  Core erythropoietin receptor signals for late erythroblast development.

Authors:  Madhu P Menon; Jing Fang; Don M Wojchowski
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

Review 4.  Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

Authors:  Charles L Bennett; Stephen Y Lai; Michael Henke; Sara E Barnato; James O Armitage; Oliver Sartor
Journal:  Arch Intern Med       Date:  2010-09-13

5.  Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease.

Authors:  Chi-Chao Chan; Emily Y Chew; Defen Shen; Joseph Hackett; Zhengping Zhuang
Journal:  Mol Vis       Date:  2005-09-01       Impact factor: 2.367

6.  Characterization of N-diethylnitrosamine-initiated and ferric nitrilotriacetate-promoted renal cell carcinoma experimental model and effect of a tamarind seed extract against acute nephrotoxicity and carcinogenesis.

Authors:  Chabetty Y Vargas-Olvera; Dolores Javier Sánchez-González; José D Solano; Francisco A Aguilar-Alonso; Fernando Montalvo-Muñoz; Claudia María Martínez-Martínez; Omar N Medina-Campos; María Elena Ibarra-Rubio
Journal:  Mol Cell Biochem       Date:  2012-07-04       Impact factor: 3.396

7.  Expression and functional significance of the erythropoietin receptor in hepatocellular carcinoma.

Authors:  Milljae Shin; Doopyo Hong; Zhengyun Zhang; You Min Kim; Wookjong Lee; Jae-Won Joh; Sung-Joo Kim
Journal:  HPB (Oxford)       Date:  2013-03-15       Impact factor: 3.647

8.  Von hippel-lindau disease.

Authors:  Frederik J Hes; Jo Wm Höppener; Rob B van der Luijt; Cornelis Jm Lips
Journal:  Hered Cancer Clin Pract       Date:  2005-11-15       Impact factor: 2.857

9.  Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.

Authors:  Tania Romina Stoyanoff; Juan Pablo Rodríguez; Juan Santiago Todaro; Joaquín Diego Espada; Juan Pablo Melana Colavita; Nora Cristina Brandan; Adriana Mónica Torres; María Victoria Aguirre
Journal:  Tumour Biol       Date:  2016-07-28

10.  Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.

Authors:  Erinn B Rankin; John E Tomaszewski; Volker H Haase
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.